Literature DB >> 18483740

[Progressive multifocal leukoencephalopathy and rheumatic disease].

C Kneitz1, H Wiendl.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare but often fatal demyelinating disease of the central nervous system induced by the JC virus. It mainly occurs in immunocompromised patients. Growing interest in rheumatology has arisen from reports of patients with rheumatic diseases suffering from PML. A direct relationship to rheumatologic disease itself, for example systemic lupus erythematosus, or to immunosuppressive therapy, is debated. Therefore, PML should be included in the differential diagnosis of non-specific neurologic symptoms and, if suspected, relevant diagnostic procedures (MRI, CSF analysis including virus-specific PCR, and possibly brain biopsy) need to be performed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483740     DOI: 10.1007/s00393-008-0297-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  18 in total

1.  Natalizumab effects on immune cell responses in multiple sclerosis.

Authors:  Masaaki Niino; Caroline Bodner; Marie-Lune Simard; Sudabeh Alatab; Dawn Gano; Ho Jin Kim; Manuela Trigueiro; Denise Racicot; Christine Guérette; Jack P Antel; Alyson Fournier; Francois Grand'Maison; Amit Bar-Or
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

2.  Natalizumab and PML.

Authors:  Richard M Ransohoff
Journal:  Nat Neurosci       Date:  2005-10       Impact factor: 24.884

3.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

Authors:  B K Kleinschmidt-DeMasters; Kenneth L Tyler
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

4.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

5.  Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population.

Authors:  P M Eng; B R Turnbull; S F Cook; J E Davidson; T Kurth; J D Seeger
Journal:  Neurology       Date:  2006-09-12       Impact factor: 9.910

6.  Progressive multifocal leukoencephalopathy in systemic lupus erythematosus.

Authors:  Venugopal Govindappa; Sarah Hicks; Melvin Wichter; Meenakshi Jolly
Journal:  Arthritis Rheum       Date:  2007-03-15

Review 7.  Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.

Authors:  Leonard H Calabrese; Eamonn S Molloy; DeRen Huang; Richard M Ransohoff
Journal:  Arthritis Rheum       Date:  2007-07

8.  Absence of imune deficiencies in a case of progressive multifocal leukoencephalopathy.

Authors:  D Rockwell; F L Ruben; A Winkelstein; H Mendelow
Journal:  Am J Med       Date:  1976-09       Impact factor: 4.965

9.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

10.  Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

Authors:  Tarek A Yousry; Eugene O Major; Caroline Ryschkewitsch; Gary Fahle; Steven Fischer; Jean Hou; Blanche Curfman; Katherine Miszkiel; Nicole Mueller-Lenke; Esther Sanchez; Frederik Barkhof; Ernst-Wilhelm Radue; Hans R Jäger; David B Clifford
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.